NASDAQ:VTVT - vTv Therapeutics Stock Price, Price Target & More

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

vTv Therapeutics Inc (NASDAQ:VTVT) announced its earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.04. The biotechnology company had revenue of $2.06 million for the quarter, compared to analyst estimates of $3.14 million. View vTv Therapeutics' Earnings History.

vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for vTv Therapeutics.

8 Wall Street analysts have issued 1-year target prices for vTv Therapeutics' stock. Their forecasts range from $4.00 to $28.00. On average, they expect vTv Therapeutics' stock price to reach $14.7143 in the next twelve months. View Analyst Ratings for vTv Therapeutics.

vTv Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totalling 977,984 shares, a decrease of 32.3% from the April 30th total of 1,444,136 shares. Based on an average trading volume of 1,462,831 shares, the days-to-cover ratio is currently 0.7 days. Currently, 14.0% of the shares of the stock are short sold. View vTv Therapeutics' Current Options Chain.

Some companies that are related to vTv Therapeutics include Galmed Pharmaceuticals (GLMD), Aratana Therapeutics (PETX), Poxel (PXXLF), Immune Design (IMDZ), Kamada (KMDA), Tetraphase Pharmaceuticals (TTPH), AcelRx Pharmaceuticals (ACRX), Teligent (TLGT), VERONA PHARMA P/S (VRNA), Ovid Therapeutics (OVID), Ardelyx (ARDX), Avid Bioservices (CDMO), VBI Vaccines (VBIV), Syndax Pharmaceuticals (SNDX) and Spero Therapeutics (SPRO).

(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Headlines about VTVT stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. vTv Therapeutics earned a media sentiment score of 0.16 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.40 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

vTv Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include MACANDREWS & FORBES INC. (79.80%), JPMorgan Chase & Co. (1.00%), C WorldWide Group Holding A S (0.30%) and Millennium Management LLC (0.29%). Company insiders that own vTv Therapeutics stock include Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.

VTVT stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., C WorldWide Group Holding A S and Millennium Management LLC. Company insiders that have bought vTv Therapeutics stock in the last two years include Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of VTVT stock can currently be purchased for approximately $1.57.

vTv Therapeutics has a market capitalization of $54.81 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-16,140,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. vTv Therapeutics employs 56 workers across the globe.

vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PARKWAY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]